Weekly shot shows promise for major weight loss in obesity trial
NCT ID NCT07481747
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a once-weekly injection called tirzepatide in about 2,500 adults with obesity or overweight who do not have type 2 diabetes. Participants receive either the drug or a placebo, along with diet and exercise advice. The main goal is to see how much weight they lose and if it is safe over 72 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?